Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin + raltitrexed continuous hepatic artery infusion for recurrent hepatocellular carcinoma after liver transplantation
ChiCTR2300073934Phase 2Recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Jul 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and raltitrexed in hepatocellular carcinoma (HCC), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Progression-free survival. Started Jul 2023; status: recruiting.
02
Drugs
oxaliplatinraltitrexed
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300073934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073934.